IgAN

Jun 20, 2025

Advancements in IgA Nephropathy (IgAN) Treatment: From Standard-of-care (SoC) to Emerging Therapies

May 27, 2025

Gilead’s TRODELVY Shows PFS Benefit in 1L Metastatic TNBC; Otsuka’s Sibeprenlimab Gets FDA Priority Review for IgA Nephropathy; Liquidia Wins FDA Nod for YUTREPIA in PAH and PH-ILD; GSK’s BLENREP Combos Get CHMP Backing in Myeloma; Relief Therapeutics Receives FDA Rare Pediatric Disease Tag for RLF-TD011

Sep 16, 2024

Travere’s FILSPARI Approval Sparks Rivalry in the IgA Nephropathy Space

Aug 19, 2024

Novartis’ FABHALTA: Leading the Way as the First Complement Inhibitor for IgAN

Aug 13, 2024

FDA Approves Ascendis Pharma’s YORVIPATH; ARS Pharma Gets FDA Green Light for First Nasal Spray; FDA Rejects Lykos’ MDMA-Assisted PTSD Therapy; Novartis’ FABHALTA Receives FDA Accelerated Approval; Servier Snags FDA Approval for Voranigo

Jul 22, 2024

4 Late-Stage IgA Nephropathy Treatment Drugs to Look Out

Newsletter/Whitepaper